Exchange: NYSEArca·Updated 07:58 PM EST

NVOX News

News
all
press releases
The request applies to GLP-1 RAs approved for obesity, including Novo Nordisk’s Wegovy and Saxenda and Eli Lilly’s Zepbound.
Stocktwits

Advertisement|Remove ads.